Weijie Lan, PhD
Dr. Weijie Lan serves as VP, Head of Cell Therapy Platform Research at Overland Pharmaceuticals.
Prior to joining Overland, Dr. Lan served as Senior Director at Walking Fish Therapeutics, where he led the efforts to build an industrial-leading B-cell therapy platform. Before Walking Fish, Weijie was a Senior Scientist at AbbVie Inc., where he built the internal platform for CAR-T cell therapy and synthesized a chimpanzee adenovirus-based vector for the oncolytic virus program. Prior to joining AbbVie, Weijie was a scientist at Fate Therapeutics, where he built the iPSC engineering platform and participated in the early development of first-in-class iPSC-derived NK and T cell therapies. Dr. Lan is a co-inventor of iPSC and B-cell engineering patents, and co-authored scientific papers in peer reviewed journals including Cell and Science. Overall, Dr. Lan brings 20 years of experience in cell biology research and cell therapy drug development.
Dr. Weijie Lan received his Ph.D. from University of Virginia and completed his post-doctoral training at the Ludwig Institute for Cancer Research at University of California San Diego. He received his Bachelor of Science degree from Wuhan University.